Quick answer: Standard cholesterol panels miss 50% of people who will have a heart attack — because they measure LDL cholesterol concentration rather than LDL particle number (ApoB), ignore LP(a) in the majority of patients, and don’t assess coronary artery calcium, the only test that directly images atherosclerotic plaque burden. Functional cardiology rebuilds cardiovascular risk assessment around ApoB, LP(a), CAC scoring, endothelial function, and root-cause cardiometabolic evaluation to identify and reverse disease long before a first event.
Cardiovascular disease remains the leading cause of death in the United States and worldwide — despite decades of statin prescribing, blood pressure treatment, and public health messaging about diet and exercise. The functional cardiology model asks: why, if we’ve had effective lipid-lowering therapies for 40 years, does cardiovascular disease continue to kill 18 million people annually? The answer, increasingly supported by precision medicine research, is that we have been measuring the wrong things, treating insufficient targets, and missing the upstream metabolic drivers that initiate atherosclerosis decades before clinical events occur.
This article examines the advanced cardiovascular biomarkers, lifestyle interventions, and integrative strategies that define modern functional cardiology — building on landmark trials while incorporating the emerging science of LP(a), TMAO, coronary artery calcium scoring, and endothelial function assessment.
ApoB: The Causal Lipoprotein — Why LDL-C Is Not Enough
Apolipoprotein B-100 (ApoB) is the single protein that coats all atherogenic lipoprotein particles — LDL, VLDL, IDL, and Lp(a). Each atherogenic particle carries exactly one ApoB molecule, making ApoB the most direct measure of the number of atherogenic particles circulating in the bloodstream. The critical insight from the past 30 years of lipid research is that it is the number of particles that determines atherosclerotic risk, not the total cholesterol mass they carry.
The discordance between LDL cholesterol (LDL-C) and LDL particle number is clinically significant and common. Patients with small, dense LDL (sdLDL) can have a normal LDL-C while having a highly elevated LDL particle number — and therefore high cardiovascular risk. Conversely, patients with large, buoyant LDL can have elevated LDL-C with a relatively normal particle count and lower risk. This “LDL discordance” is most common in patients with insulin resistance, metabolic syndrome, and hypertriglyceridemia — precisely the populations where cardiovascular risk is underestimated by LDL-C alone.
Multiple prospective studies have confirmed that ApoB is superior to LDL-C for cardiovascular risk prediction. The AMORIS study (Walldius and colleagues, 2001, Lancet), following 175,553 subjects, found ApoB to be the strongest predictor of fatal myocardial infarction across all lipid markers tested. Meta-analyses have consistently found that when LDL-C and ApoB are discordant, ApoB predicts risk more accurately. The Canadian Cardiovascular Society and European Society of Cardiology guidelines now recommend ApoB as a preferred lipid target over calculated LDL-C.
Optimal ApoB target levels depend on overall cardiovascular risk profile: <65 mg/dL for very high-risk patients (established ASCVD or familial hypercholesterolemia), <80 mg/dL for high-risk, and <100 mg/dL for low-to-moderate risk. Many functional cardiologists target ApoB <70 mg/dL for primary prevention in patients with multiple risk factors, reasoning that the population with the lowest documented CVD rates (traditional plant-dominant cultures) typically have ApoB in the 40–60 mg/dL range.
Lipoprotein(a): The Genetic Cardiovascular Risk Factor in 20% of the Population
Lipoprotein(a) — LP(a) — is an LDL-like particle with an additional apolipoprotein(a) protein moiety attached via a disulfide bond. Approximately 20% of the general population carries LP(a) levels above 50 mg/dL (roughly 100 nmol/L in mass units), a threshold associated with significantly elevated atherosclerotic cardiovascular disease (ASCVD) and aortic valve stenosis risk. LP(a) levels are 80–90% genetically determined, driven by the number of “kringle IV” repeats in the LPA gene, and are largely unresponsive to lifestyle modifications or standard lipid-lowering therapies.
Nordestgaard and colleagues’ 2010 JAMA meta-analysis of 36 prospective studies (n=126,634) found that LP(a) >50 mg/dL was associated with a hazard ratio of 1.5 for coronary heart disease and 1.4 for stroke, independent of traditional risk factors. A 2019 Mendelian randomization study in JAMA Cardiology demonstrated a dose-dependent causal relationship between genetically elevated LP(a) and ASCVD — confirming LP(a) as a causal rather than merely associative risk factor.
Despite this, LP(a) is not routinely measured in standard cardiovascular panels — a major gap, as a patient with LP(a) of 200 nmol/L and a normal LDL-C may be falsely reassured by their conventional lipid panel while carrying triple the population-average cardiovascular risk. Current functional cardiology practice includes LP(a) in all initial cardiovascular risk assessments, at minimum once per lifetime (as levels are genetically stable).
Novel LP(a)-lowering therapies are in late-stage development. Pelacarsen (an antisense oligonucleotide) reduced LP(a) by over 80% in Phase 2 trials, and olpasiran (siRNA targeting the LPA gene) achieved 95%+ LP(a) reduction in the OCEAN(a)-DOSE trial (O’Donoghue and colleagues, 2022, NEJM). Phase 3 outcomes trials are ongoing. In the interim, the functional approach focuses on identifying elevated LP(a) to intensify control of modifiable risk factors — particularly LDL-C/ApoB reduction, blood pressure control, and insulin resistance management — to reduce overall plaque burden.
Coronary Artery Calcium Scoring: The Direct Visualization of Plaque
Coronary artery calcium (CAC) scoring — a low-dose non-contrast CT scan that quantifies calcified plaque in the coronary arteries — is the only widely available test that directly images atherosclerotic burden rather than estimating it from risk factors. It is the most powerful cardiovascular risk stratification tool currently available for asymptomatic intermediate-risk individuals, superior to traditional risk calculators (Framingham, Pooled Cohort Equation) in predicting future events.
The MESA (Multi-Ethnic Study of Atherosclerosis) study, following 6,814 participants over 10+ years, demonstrated that CAC score of 0 is associated with a 10-year major cardiovascular event rate of less than 1% — identifying a low-risk group who may not benefit from statin therapy despite having intermediate calculated risk. The 2019 ACC/AHA Guideline on Cardiovascular Risk Reduction formally endorsed CAC scoring as a decision aid when the risk-benefit of statin therapy is uncertain. A CAC of zero in a 55-year-old with borderline calculated risk can defer statin initiation; a CAC of 400 in the same patient argues for aggressive medical and lifestyle intervention.
The EISNER trial (Rozanski and colleagues, 2011, JACC) demonstrated that CAC disclosure produced significant reductions in LDL-C, systolic blood pressure, weight, and 10-year Framingham risk score compared to non-disclosure — suggesting that seeing one’s own plaque burden has a powerful behavior-change effect beyond what risk score communication achieves. In functional practice, CAC is often the most motivating single test for patients who are ambivalent about lifestyle change.
Endothelial Function: The First Stage of Atherosclerosis
Atherosclerosis begins not with lipid deposition but with endothelial dysfunction — the loss of the vascular endothelium’s ability to produce nitric oxide (NO) and maintain vascular homeostasis. Endothelial dysfunction precedes and predicts clinical cardiovascular events, often by decades. The endothelium maintains vascular tone, prevents platelet aggregation, regulates vascular permeability, and modulates inflammation through NO-dependent mechanisms; its dysfunction allows LDL particles — particularly small, dense LDL and oxidized LDL — to penetrate the arterial intima and initiate the inflammatory cascade that becomes atherosclerotic plaque.
The biochemical basis of endothelial dysfunction involves oxidative stress: superoxide anion (O₂⁻) from multiple cellular sources — activated NADPH oxidase, mitochondrial electron transport chain leak, xanthine oxidase — reacts with NO at near-diffusion-limited rates to form peroxynitrite (ONOO⁻), reducing NO bioavailability while simultaneously oxidizing LDL particles and damaging vascular wall proteins. Insulin resistance drives endothelial dysfunction directly: insulin normally stimulates eNOS (endothelial nitric oxide synthase) via PI3K-Akt signaling, and this pathway is selectively impaired in insulin-resistant states while the pro-atherogenic ERK/MAPK pathway remains active.
L-arginine (the substrate for eNOS) and L-citrulline (which is recycled to L-arginine) have been studied as means to support NO production, though with mixed clinical results reflecting the “arginine paradox” — the finding that intracellular L-arginine is not typically rate-limiting for eNOS under normal conditions. More promising is the dietary nitrate → nitrite → NO pathway: inorganic nitrate from green leafy vegetables and beetroot is reduced to nitrite by oral bacteria, then further reduced to NO in the acidic gastric environment and in ischemic tissues. Larsen and colleagues (2007, Acta Physiologica) demonstrated that dietary nitrate from beetroot juice reduced blood pressure by 10/8 mmHg within hours in healthy subjects — an effect replicated and confirmed by multiple subsequent RCTs.
The PREDIMED Trial: Mediterranean Diet and Cardiovascular Event Reduction
The Prevención con Dieta Mediterránea (PREDIMED) trial represents the strongest dietary RCT evidence for cardiovascular risk reduction. The study enrolled 7,447 high-risk participants in Spain (without established CVD at baseline) and randomized to three interventions: Mediterranean diet supplemented with extra-virgin olive oil (EVOO), Mediterranean diet supplemented with mixed nuts, or low-fat control diet, with a primary endpoint of major cardiovascular events.
The original 2013 publication in the New England Journal of Medicine reported a 30% reduction in MACE (HR 0.70, 95% CI 0.54–0.92) for the EVOO group and 28% reduction (HR 0.72, 95% CI 0.54–0.96) for the nuts group compared to low-fat diet, with early stopping for efficacy after a median 4.8 years. A 2018 re-analysis with corrected statistical methodology confirmed the significant benefit, though with slightly attenuated effect sizes.
The active components of the Mediterranean diet’s cardiovascular benefit are thought to include: polyphenols in EVOO (oleocanthal, oleuropein) with NF-κB inhibitory and antioxidant properties; omega-3 fatty acids from fatty fish (EPA and DHA); fiber-driven favorable gut microbiome modulation; and the overall reduction in refined carbohydrates and processed foods that characterizes the traditional Mediterranean pattern. The nuts group benefited from walnut ALA content (an omega-3 precursor), magnesium, arginine, and polyphenols including ellagitannins from walnuts that are metabolized by gut bacteria to urolithins with anti-inflammatory properties.
Omega-3 Fatty Acids and REDUCE-IT: Clarifying the Evidence
The omega-3 fatty acid EPA (eicosapentaenoic acid) achieved renewed cardiovascular interest with the REDUCE-IT trial (Bhatt and colleagues, 2019, New England Journal of Medicine), which demonstrated a 25% relative risk reduction in MACE with icosapentaenoic acid (IPE/Vascepa, a highly purified EPA ester) 4g/day compared to mineral oil placebo in high-risk patients with elevated triglycerides already on statin therapy. The effect size was unexpectedly large and prompted significant debate about whether the benefit arose from EPA’s anti-inflammatory, anti-atherosclerotic properties, or whether the mineral oil placebo (which raised LDL-C and hsCRP in the control group) inflated the apparent benefit.
The STRENGTH trial using a DHA+EPA combination (omega-3 carboxylic acids) showed no benefit versus corn oil placebo — though the control arm used a different, more neutral comparator. The mechanistic data supporting EPA specifically is substantial: EPA reduces arachidonic acid incorporation into cell membranes (reducing pro-inflammatory eicosanoid production), decreases hepatic VLDL secretion, and has direct anti-atherogenic effects on plaque stabilization demonstrated in IVUS (intravascular ultrasound) studies. The meta-analytic signal from omega-3 trials supports moderate cardiovascular benefit (13–25% relative risk reduction) particularly at higher doses and in patients with elevated triglycerides.
CoQ10, Statins, and Mitochondrial Cardiovascular Health
Coenzyme Q10 (CoQ10/ubiquinone) is an essential electron carrier in the mitochondrial respiratory chain (Complex I → Complex III) and the most concentrated lipid-soluble antioxidant in the body, with particularly high expression in cardiomyocytes. Statins inhibit HMG-CoA reductase — the same enzyme that produces cholesterol — but also deplete CoQ10 because CoQ10 synthesis shares the mevalonate pathway upstream of HMG-CoA reductase. Circulating CoQ10 levels fall 30–50% with standard statin doses.
The clinical question of whether statin-induced CoQ10 depletion causes muscle symptoms (myalgia, myopathy) and whether CoQ10 supplementation mitigates this has been studied in multiple RCTs with mixed results: the STATCOPE trial (Banach and colleagues, 2015, Mayo Clinic Proceedings) found that CoQ10 200mg/day did not significantly reduce statin-related muscle symptoms compared to vitamin E or placebo. However, observational data and some smaller trials suggest that patients with the most severe CoQ10 depletion and documented mitochondrial dysfunction benefit most from supplementation. Functional practice typically includes CoQ10 (ubiquinol form for better bioavailability, 100–400mg daily) in statin-treated patients with myalgia, elevated CK, or significant fatigue, particularly in those over 65 where baseline CoQ10 levels are already reduced.
Beyond the statin-CoQ10 question, CoQ10 has independent evidence for heart failure. The Q-SYMBIO trial (Mortensen and colleagues, 2014, JACC Heart Failure) randomized 420 severe heart failure patients to CoQ10 300mg/day versus placebo for 2 years, finding 43% relative reduction in all-cause mortality (HR 0.57, 95% CI 0.36–0.92) — the first study in over a decade to show mortality benefit in heart failure beyond standard of care. This trial positioned CoQ10 as potentially the most impactful non-pharmaceutical intervention available for HFrEF patients.
Homocysteine: The Inflammatory-Thrombotic Cardiovascular Risk Marker
Homocysteine — a sulfur-containing amino acid produced during methionine metabolism — accumulates when the remethylation pathway (requiring folate and B12) or the transsulfuration pathway (requiring B6) is impaired. Elevated homocysteine damages endothelial cells directly, promotes LDL oxidation, activates platelets, impairs fibrinolysis, and stimulates vascular smooth muscle cell proliferation — a constellation of effects that mechanistically explains its consistent association with cardiovascular events.
Wald and colleagues’ 2002 BMJ meta-analysis found that each 5 μmol/L increase in homocysteine was associated with a hazard ratio of 1.32 for coronary artery disease and 1.59 for stroke — comparable to the risk from a 20 mmHg increase in systolic blood pressure. The functional threshold for concern is homocysteine ≥10 μmol/L, with optimal levels considered to be <7–8 μmol/L.
Homocysteine is reliably lowered by B-vitamin supplementation (folate 400–1,000 mcg, B12 500–1,000 mcg, B6 25–50 mg). However, several large RCTs (VISP, HOPE-2, NORVIT) showed that B-vitamin-mediated homocysteine lowering did not significantly reduce cardiovascular events in patients with established CVD — leading some to question homocysteine’s causality. The more nuanced interpretation is that B-vitamin supplementation in the context of already-treated CVD may be too late-stage, and that the intervention window for homocysteine is in primary prevention — particularly in individuals with MTHFR polymorphisms (C677T, A1298C) that reduce folate metabolism efficiency. The functional medicine approach identifies MTHFR status and optimizes methylation capacity as a primary prevention strategy.
TMAO: The Gut-Cardiovascular Connection
Trimethylamine N-oxide (TMAO) has emerged as a microbially-produced cardiovascular risk factor that links dietary patterns, gut microbiome composition, and atherosclerotic disease. Red meat and egg yolk contain phosphatidylcholine and L-carnitine, which gut bacteria metabolize to trimethylamine (TMA); TMA is then converted by hepatic flavin monooxygenase 3 (FMO3) to TMAO.
The landmark Tang and colleagues 2013 NEJM study demonstrated that plasma TMAO levels in 4,007 patients undergoing cardiac evaluation predicted 3-year MACE independently of traditional risk factors, with hazard ratios of 2.5 in the highest versus lowest quartile. Mechanistically, TMAO impairs reverse cholesterol transport by reducing hepatic bile acid synthesis and CYP7A1 expression, promotes foam cell formation and plaque instability, and activates the NLRP3 inflammasome in macrophages. Dietary interventions that reduce TMAO-producing microbial taxa — particularly Mediterranean and plant-dominant diets, resveratrol, 3,3-dimethyl-1-butanol (DMB, found in extra-virgin olive oil), and intermittent fasting — represent modifiable routes to TMAO reduction.
Blood Pressure Optimization: Root Causes and Functional Interventions
Hypertension — present in nearly half of U.S. adults using the 2017 ACC/AHA definition of ≥130/80 mmHg — is the single largest attributable risk factor for cardiovascular mortality globally. The functional cardiology approach treats hypertension as a syndrome of multiple underlying mechanisms rather than a diagnosis to be managed with blood pressure drugs alone.
The primary root causes of essential hypertension include: insulin resistance (hyperinsulinemia activates the sympathetic nervous system and promotes sodium retention), sodium-potassium imbalance (modern diets provide ~10× more sodium than potassium, opposite the 1:10 ratio humans evolved with), magnesium deficiency (magnesium relaxes vascular smooth muscle via calcium channel antagonism), oxidative stress and endothelial dysfunction (impairing NO-mediated vasodilation), and HPA axis dysregulation (elevated cortisol promotes sodium retention and vasoconstriction).
The DASH diet — Dietary Approaches to Stop Hypertension — reduced systolic blood pressure by 11.4 mmHg in hypertensive individuals in the original 1997 NEJM trial, with the blood pressure-lowering effect attributable primarily to increased potassium, magnesium, and calcium from fruits, vegetables, and low-fat dairy. Dietary nitrate from green leafy vegetables provides an additional 4–10 mmHg reduction via the nitrate-nitrite-NO pathway. The combination of DASH diet, exercise, and sodium restriction in the ENCORE trial achieved blood pressure reductions comparable to first-line antihypertensive drug therapy in stage 1 hypertensives — the evidence base for lifestyle-first treatment in non-urgent hypertension.
Frequently Asked Questions About Functional Cardiology
What is the single most important cardiovascular test I should have that I probably don’t?
For most adults over 40 with any cardiovascular risk factors, a coronary artery calcium (CAC) scan is the highest-yield test they probably haven’t had. A CAC of 0 can provide genuine reassurance and may justify deferring statin therapy. A CAC above 100 in a 45-year-old provides decisive motivation for aggressive lifestyle and medical intervention — and the knowledge that intervention at this stage, before a clinical event, is when it matters most. LP(a) measurement comes a close second: a test done once in a lifetime can identify the 20% of people carrying a genetic risk factor they have no awareness of.
Do I need a statin if my LDL-C is high but my CAC is zero?
The 2019 ACC/AHA guidelines explicitly endorse CAC scoring in this decision. A CAC of 0 in a patient with borderline calculated risk can reasonably justify deferring statin initiation — with lifestyle optimization and repeat assessment in 3–5 years. However, this decision is more nuanced if LP(a) is elevated (which can drive events even without calcified plaque), if ApoB is significantly elevated, or if there is strong family history of premature CVD. The discussion should occur with your clinician in the context of your full risk picture.
Can cardiovascular disease be reversed?
Coronary artery plaque regression has been demonstrated in clinical trials. The ASTEROID trial (2006, JAMA) showed statistically significant coronary plaque regression with high-intensity rosuvastatin therapy, measured by intravascular ultrasound. Plant-based dietary interventions (Ornish 1990 Lancet trial) demonstrated coronary angiographic improvement and reduced angina with intensive lifestyle modification. The evidence suggests that plaque progression can be halted and even reversed with sufficiently aggressive lipid lowering (ApoB <60 mg/dL), blood pressure control, insulin resistance reversal, inflammation reduction, and smoking cessation. What cannot be reversed is calcification — hence the urgency of early detection and prevention before plaque becomes calcified.
Is inflammation or cholesterol more important for cardiovascular risk?
Both are necessary; neither alone is sufficient. The “response-to-retention” model of atherosclerosis explains that LDL particles (measured by ApoB) must enter the arterial wall and trigger an inflammatory response to produce plaque. The CANTOS trial (Ridker and colleagues, 2017, NEJM) showed that canakinumab — targeting IL-1β inflammation without affecting lipids — reduced cardiovascular events by 15%, confirming that inflammation is an independent causal target. High-sensitivity CRP >2 mg/L identifies a high-residual-inflammatory-risk group that may benefit from anti-inflammatory interventions (colchicine, low-dose methotrexate, omega-3 acids, dietary pattern changes) beyond lipid lowering.
What is the optimal blood pressure target?
The SPRINT trial (2015, NEJM) demonstrated that intensive blood pressure lowering to <120/80 mmHg reduced cardiovascular events and all-cause mortality compared to the <140/90 mmHg target in non-diabetic adults at high cardiovascular risk. However, the benefit was concentrated in older adults; benefit in younger patients at lower baseline risk is less certain. The 2017 ACC/AHA guideline lowered the treatment threshold to ≥130/80 mmHg based largely on SPRINT. In functional cardiology, the target is typically 110–120/70–75 mmHg as the population with lowest demonstrated cardiovascular risk — achieved through lifestyle optimization first, with pharmaceutical support when needed.
Building Your Functional Cardiovascular Assessment
Comprehensive functional cardiovascular risk assessment typically includes: ApoB (primary lipid target), LP(a) (once per lifetime), advanced lipid panel (sdLDL, HDL subfractions, VLDL particle number), fasting insulin and HOMA-IR, HbA1c, high-sensitivity CRP and fibrinogen, homocysteine, TMAO (in high red meat consumers), 25-OH vitamin D, CAC score (for intermediate-risk patients aged 40–75), resting 12-lead ECG, and blood pressure with orthostatic measurements. DUTCH Complete or salivary cortisol testing may be added when HPA axis dysregulation is suspected as a contributing factor.
Cardiovascular disease is not fate. It is the predictable consequence of decades of metabolic insults — insulin resistance, oxidative stress, endothelial dysfunction, and lipoprotein accumulation — that can be identified early and addressed systematically. If you have cardiovascular risk factors, a family history of premature heart disease, or simply want to know your true cardiovascular age rather than your calendar age, a functional cardiology evaluation can provide the precision picture that standard testing does not. To schedule your advanced cardiovascular evaluation at The Private Practice, call (810) 206-1402.